



POSTER ABSTRACT PRESENTATIONS SESSION TITLE: POSTER SESSION 3

# Abstract 550: Magnetic Nanoparticle-mediated Targeting Of Endothelium To Address Restenosis In A Bioprinted *In Vitro* Model Of Pulmonary Arteries

Liqun Ning, Martin L Tomov, Stefano Zanella, Byron Zambrano, Reza Avazmohammadi, Morteza Mahmoudi, Holly Bauser-Heaton and Vahid Serpooshan

**Originally published** 30 Nov 2022 https://doi.org/10.1161/atvb.42.suppl\_1.550 Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42:A550

### **Abstract**

Vascular restenosis is a major complication in recanalized arteries. Nanoparticles (NPs) have shown great promise as delivery systems in advancing strategies to treat such vascular anomalies. By enabling precise targeting, NPs can overcome the challenges of low drug efficacy and off-target effects. Here we present a biomimetic *in vitro* platform comprised of 3D bioprinting, nanomaterials, and perfusion technologies, to study the use of NP targeting to address endothelial overgrowth. We bioprinted 3D vascular channels at high fidelity, using gelatin methacrylate as bioink, with artery-like stiffness. Human endothelial cells (ECs) were used to endothelialize the printed channels. GFP-labelled superparamagnetic iron oxide NPs (SPIONs), loaded with the *Rapamune* anti-proliferative drug, were perfused through the bifurcated artery model at physiological rate. Computational modeling predicted greatest level of alterations in wall shear stress in the conduit's junction with the artery, identifying this region prone to restenosis. A neodymium disc magnet was embedded in the printed tissue to attract the therapeutic SPIONs to the region of high risk. *In vitro* dynamic culture was conducted for 2 wks. We assessed cell viability, proliferation, and function using AlamarBlue and immunohistochemistry. Results showed

significant targeted effect of NP delivery in reducing EC overgrowth. This platform enables design of precise targeting of therapeutics to treat a variety of cardiovascular diseases at a high spatial and temporal control.




Figure 1. A 3D model of anastomosed arteries is bioprinted (A), housed in a customized perfusion chamber (B-C), and perfused with media containing drug-loaded SPIONs (D). E: CFD modeling assessed flow hemodynamics in 3D artery model. F-G: Vascular constructs are seeded with endothelial cells and cultured under flow. The effect of magnetic targeting of therapeutic SPIONs on EC function was evaluated by IHC (F) and AlamarBlue (G) assays.

Download figure

#### **Footnotes**

Author Disclosures: For author disclosure information, please visit the AHA Vascular Discovery: From Genes to Medicine 2022 Scientific Sessions Online Program Planner and search for the abstract title.

<

∧ Back to top

## Arteriosclerosis, Thrombosis, and Vascular Biology

#### **AHA Journals**

Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)

Circulation

Circ: Arrhythmia and Electrophysiology
Circ: Genomic and Precision Medicine

Circ: Cardiovascular Imaging

Circ: Cardiovascular Interventions

Circ: Cardiovascular Quality & Outcomes

Circ: Heart Failure
Circulation Research

Hypertension

Journal of the American Heart Association (JAHA)

Stroke

Stroke: Vascular and Interventional Neurology

AIM: Clinical Cases

#### **Journal Information**

About ATVB

**Editorial Board** 

Meet the Editors

Reprints

**Customer Service and Ordering Information** 

AHA Journals RSS Feeds

For International Users

Institutions/Librarians FAQ

For Subscribers

Subscriber Help

Wolters Kluwer Privacy Policy

#### **Subjects**

All Subjects

Arrhythmia and Electrophysiology

Basic, Translational, and Clinical Research

Critical Care and Resuscitation

Epidemiology, Lifestyle, and Prevention

Genetics

Heart Failure and Cardiac Disease

Hypertension

Imaging and Diagnostic Testing

Intervention, Surgery, Transplantation

**Quality and Outcomes** 

Stroke

Vascular Disease

#### **Features**

Cover Art Award

Early Career Opportunities

ATVB in Focus

Recent Brief Reviews of ATVB

Lecture Series

Recent Highlights of ATVB

Commentaries

**Browse Abstracts** 

Insight into ATVB Authors

#### **Resources & Education**

AHA Guidelines and Statements

Council on ATVB

Information for Advertisers


#### For Authors & Reviewers

Instructions for Authors

Submission Site

AHA Journals EDI Editorial Board

**Author Reprints** 





# American Heart Association®

#### **National Center**

7272 Greenville Ave. Dallas, TX 75231

#### **Customer Service**

1-800-AHA-USA-1 1-800-242-8721

Local Info

**Contact Us** 

#### **ABOUT US**

About the AHA/ASA	/
Annual Report	>
AHA Financial Information	>
Careers	>
SHOP	>
Latest Heart and Stroke News	>
AHA/ASA Media Newsroom	>
Global Programs	>
OUR SITES	
American Heart Association	>
American Stroke Association	>
Professional Heart Daily	>
More Sites	>
TAKE ACTION	
Advocate	>
Donate	>
Planned Giving	>

Volunteer	>
ONLINE COMMUNITIES	
AFib Support	>
Garden Community	>
Patient Support Network	>
Privacy Policy   Copyright   Ethics Policy   Conflict of Interest Policy   Linking Policy   Diversity   Careers   Suppliers & Providers   Accessibility Statement   State Fundraising Notices	

© American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization.

<sup>\*</sup>Red Dress ™ DHHS, Go Red ™; AHA; National Wear Red Day ® is registered trademark.







6 of 6